30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

DiscGenics Treats First Patient in IDCT Trial -

The first patient has been treated in DiscGenics' Phase I/II U.S. clinical trial of IDCT injection to treat mild to moderate degenerative disc disease. IDCT is an allogeneic cell therapy comprising Discogenic Cells and a viscous scaffold. During treatment, a dose of IDCT is injected percutaneously into the disc. The prospective, randomized, double-blinded, vehicle- and placebo-controlled 10-center trial will enroll 60 subjects, evaluating safety and preliminary efficacy of IDCT at varying dosage levels. (DiscGenics, Inc., 4/26/18)